Enter your terms above and click the 'Search' button.

Showing articles 0 to 12 of 12 Filter Applied: immunosuppressive agents (Click to remove) Myasthenia Gravis NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016 Ocular Myasthenia:A Protean Disorder Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994 Pregnancy in Patients with AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder Neurol 96:e2006-e2015, Collongues, N.,et al, 2021 International Consensus Guidance for Management of Myasthenia Gravis Neurol 87:419-425, Sanders, D.B.,et al, 2016 The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome JNNP 82:671-673, Maddison, P.,et al, 2011 Management of Myasthenia Gravis Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004 Treatment of Acquired Myasthenia Gravis Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997 Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies Ann Neurol 37:S63-S73, Sanders,D.B., 1995 Myasthenia Gravis NEJM 330:1797-1810, Drachman,D.B., 1994 Plasma Exchange & Immunosuppressive Drug Treatment in the Lambert-Eaton Myasthenic Syndrome Neurol 34:480-485, Newsom-Davis,J.,et al, 1984 Plasmapheresis & Immunosuppressive Drug Therapy in the Eaton-Lambert Syndrome Ann Neurol 11:570-575, Da,P.C.,et al, 1982 Controversies About the Treatment of Myasthenia Gravis JNNP 43:644-659, Rowland,L.P., 1980 Showing articles 0 to 12 of 12